Edition:
India

Ascendis Pharma A/S (ASND.OQ)

ASND.OQ on NASDAQ Stock Exchange Global Select Market

55.81USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$55.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
36,078
52-wk High
$56.77
52-wk Low
$21.95

Latest Key Developments (Source: Significant Developments)

Ascendis Pharma Initiates Submissions In Australia To Enter Study With Transcon CNP
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Ascendis Pharma A/S ::ASCENDIS PHARMA SAYS ON DEC 20, INITIATED REGULATORY SUBMISSIONS IN AUSTRALIA TO ENTER INTO FIRST HUMAN CLINICAL STUDY WITH TRANSCON CNP - SEC FILING.  Full Article

Ascendis Pharma A/S Q3 loss per share EUR 1.04
Friday, 17 Nov 2017 

Nov 16 (Reuters) - Ascendis Pharma A/S ::Ascendis Pharma A/S reports third quarter 2017 financial results.Q3 loss per share EUR 1.04.Q3 earnings per share view EUR -0.74 -- Thomson Reuters I/B/E/S.  Full Article

Ascendis Pharma reports Q2 loss per share EUR 0.53
Thursday, 1 Sep 2016 

Ascendis Pharma A/S : Ascendis Pharma A/S reports second quarter 2016 financial results and provides business update . Q2 loss per share eur 0.53 . Qtrly revenue euro 1.1 million versus euro 1.9 million .Q2 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

Ascendis Pharma A/S files for potential share offering of up to $250 mln
Saturday, 21 May 2016 

Ascendis Pharma A/S :Ascendis Pharma A/S files for potential share offering of up to $250 million - SEC filing.  Full Article

Ascendis Pharma A/S reports Q1 loss of 0.82 euros per share
Friday, 20 May 2016 

Ascendis Pharma A/S : Ascendis Pharma A/S reports first quarter 2016 financial results . Q1 loss per share eur 0.82 .Q1 revenue fell 40 percent to eur 1.3 million.  Full Article

BRIEF-Ascendis Pharma Says Completed Target Enrollment In Phase 3 Trial Of Pediatric Growth Hormone Deficiency Treatment

* ASCENDIS PHARMA ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN PHASE 3 TRIAL OF TRANSCON GROWTH HORMONE FOR PEDIATRIC GROWTH HORMONE DEFICIENCY